Overview

Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 Combined With Irinotecan in the Treatment of Recurrent and Metastatic Esophageal Squamous Cell Carcinoma.

Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of si-B001 monotherapy RP2D and single-dose low-dose combined with irinotecan in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) obtained in phase I clinical trials. To evaluate the safety and tolerability of si-B001 monotherapy RP2D and single-dose low-dose combined with irinotecan in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) obtained in phase I clinical trials.
Phase:
Phase 2
Details
Lead Sponsor:
Sichuan Baili Pharmaceutical Co., Ltd.